Imatinib mesylate - The new gold standard for treatment of chronic myeloid leukemia

被引：127

作者：

Peggs, K ^{[1
]}

Mackinnon, S ^{[1
]}

机构：

[1] UCL Royal Free & UCL Med Sch, London, England

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2003年 / 348卷 / 11期

关键词：

D O I：

10.1056/NEJMe030009

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1048 / 1050

页数：4

共 10 条

[1]

Branford S, 2002, BLOOD, V100, p96A

[2]

Delannoy A, 1997, J NATL CANCER I, V89, P1616

[3] Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].

Druker, BJ ;

Talpaz, M ;

Resta, DJ ;

Peng, B ;

Buchdunger, E ;

Ford, JM ;

Lydon, NB ;

Kantarjian, H ;

Capdeville, R ;

Ohno-Jones, S ;

Sawyers, CL .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037

[4]

Druker BJ, 2001, NEW ENGL J MED, V345, P232

[5] Implications of imatinib mesylate for hematopoietic stem cell transplantation [J].

Goldman, J .

SEMINARS IN HEMATOLOGY, 2001, 38 (03) :28-34

[6] Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation [J].

Gratwohl, A ;

Hermans, J ;

Goldman, JM ;

Arcese, W ;

Carreras, E ;

Devergie, A ;

Frassoni, F ;

Gahrton, G ;

Kolb, H ;

Niederwieser, D ;

Ruutu, T ;

Vernant, JP ;

de Witte, T ;

Apperley, J .

LANCET, 1998, 352 (9134) :1087-1092

[7] A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa [J].

Hasford, J ;

Pfirrmann, M ;

Hehlmann, R ;

Allan, NC ;

Baccarani, M ;

Kluin-Nelemans, JC ;

Alimena, G ;

Steegmann, JL ;

Ansari, H .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (11) :850-858

[8] Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia [J].

O'Brien, SG ;

Guilhot, F ;

Larson, RA ;

Gathmann, I ;

Baccarani, M ;

Cervantes, F ;

Cornelissen, JJ ;

Fischer, T ;

Hochhaus, A ;

Hughes, T ;

Lechner, K ;

Nielsen, JL ;

Rousselot, P ;

Reiffers, J ;

Saglio, G ;

Shepherd, J ;

Simonsson, B ;

Gratwohl, A ;

Goldman, JM ;

Kantarjian, H ;

Taylor, K ;

Verhoef, G ;

Bolton, AE ;

Capdeville, R ;

Druker, BJ ;

Durrant, S ;

Schwarer, A ;

Joske, D ;

Seymour, J ;

Grigg, A ;

Ma, D ;

Arthur, C ;

Bradstock, K ;

Joshua, D ;

Louwagie, A ;

Martiat, P ;

Straetmans, N ;

Bosly, A ;

Shustik, C ;

Lipton, J ;

Forrest, D ;

Walker, I ;

Roy, DC ;

Rubinger, M ;

Bence-Bruckler, I ;

Kovacs, M ;

Turner, AR ;

Birgens, H ;

Bjerrum, O ;

Facon, T .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (11) :994-1004

[9] Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl-positive cells [J].

Thiesing, JT ;

Ohno-Jones, S ;

Kolibaba, KS ;

Druker, BJ .

BLOOD, 2000, 96 (09) :3195-3199

[10] Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs [J].

Tipping, AJ ;

Mahon, FX ;

Zafirides, G ;

Lagarde, V ;

Goldman, JM ;

Melo, JV .

LEUKEMIA, 2002, 16 (12) :2349-2357

← 1 →